- Home
- Technology
- Services
- mRNA Display-based Antibody Discovery
- mRNA Display-based Peptide Discovery
- mRNA Display-based Protein Discovery
- Applications
- About
Viruses have become the pathogen of major epidemics. Identifying the potential targets of viruses is particularly important for success. Antibodies and antibody fragments occupy an important therapeutic means against infectious diseases. Because of their high affinity, they can be designed and engineered for a variety of purposes to develop therapeutic and diagnostic reagents. CD BioSciences has many years of research experience in the field of antibody discovery, and is committed to providing antivirus antibody discovery and screening services for customers around the world using its antibody discovery platform based on mRNA display.
The outbreak and prevalence of viral infectious diseases pose a serious threat to social and economic activities and human life and health, and they are accelerating. Discovering and developing efficient therapies is an urgent requirement to prevent viral outbreaks and epidemics. Monoclonal antibodies (mAbs) have played an undisputed role in eradicating infections due to their unique targeting specificity. mAbs neutralize the virus by blocking the interaction between the virus and the host cell by binding to free virus or to the required receptors on the cell surface to attach the virus and enter the cell. They also help eliminate viral infections by presenting antigens presented on infected target cells (through opsonization of infected cells) to immune system effector cells.
Fig. 1 Induction of Life-Long Protective Immunity Against FrCasE by Neutralizing Antiviral mAbs. (Pelegrin, et al., 2015)
The therapeutic use of antiviral antibodies faces several obstacles, including their complexity, large size, interaction with the patient's immune system, and insufficient pharmacokinetics. It is of great value to use the in vitro display method to screen recombinant antibodies and antibody fragments with different specificities and affinities from antibody libraries to overcome the shortcomings of existing therapeutic antibodies. For example, puromycin-based mRNA display technology that physically links proteins to nucleic acid tags can be used for antibody screening against any viral antigen, and the introduction of random mutations during the display cycle can generate optimal ligands with desired properties for targeting. Based on the high-throughput characteristics of mRNA display technology and the screening conditions not controlled by cells, it is an excellent technology platform for generating antibodies or antibody fragments with enhanced performance.
CD BioSciences has built a high-throughput antibody discovery platform based on mRNA display technology, which can provide global customers with antibody screening services for different viral targets. Our antibody discovery platform achieves targeted screening by covalently linking proteins and nucleic acids. After a series of purification and PCR amplification cycles, target antibodies and their DNA sequences with enhanced properties can be obtained simultaneously. Viruses that can be targeted include, but are not limited to:
If there are virus targets you are interested in, or you do not find the desired choice in our services, you only need to provide relevant project information, and our expert team can design the best solution for your project.
High-throughput Screening
Fast Turnaround Time
Customized Service
Various Antibody Types
CD BioSciences has many years of project development experience in antibody discovery. Based on the mRNA display technology platform, it can provide customers with various types of antibody screening services. If you are interested in our services, please contact us for more details.
References
